Cell Dissociation Market set to Top a Valuation of US$ 1257.59 Million by 2033 & exhibit a CAGR of 13.55% over the forecast period | Future Market Insights, Inc.

Cell dissociation, also known as trypsinization, is the process of separating adherent cells from the cell culture vessel by breaking down proteins with the help of a proteolytic enzyme. The cell dissociation market is growing rapidly due to a rising need for cell-based tests and biopharmaceuticals. Enzymes, antibodies, and equipment make up the majority of the market-available products for cell dissociation


NEWARK, Del, June 07, 2023 (GLOBE NEWSWIRE) -- The Cell Dissociation Market worth US$ 352.91 million by 2023, with a 13.55% CAGR from 2023 to 2033. By 2033, the cell dissociation industry is set to reach US$ 1257.59 million. The pharmaceutical and healthcare industries' accelerated concentration on expenditure, and research and development fuels market expansion.

Synopsis of the Global Cell Dissociation Market

The cell dissociation industry is booming as a result of accelerated research and development spending by biopharmaceutical companies. Cell dissociation is an essential task in biopharmaceutical research as it's directly involved in medicine creation and pathophysiology explanation.

Get your PDF Sample Report with Latest Market Information @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16892

The biopharmaceutical sector is a dynamically developing segment of the pharmaceutical industry, with significant consequences for healthcare. Opportunities in biopharmaceuticals have emerged in the previous decade as a result of their excellent efficacy and safety.

Many benefits of using biopharmaceuticals, including reduced side effects, and the possibility to treat the underlying cause of an illness have increased demand for medicines. There is growth in public and private investment due to the advent of products with better tissue dissociation enzymes. As a result, the cell dissociation industry flourished.

There are limited cell dissociation industry growth restrictions, despite the several significant market determinants. The cell dissociation industry growth may be constrained by soft tissue operations' high cost.

Another factor that could slow the cell dissociation market growth is the preference for enzyme-free over enzymatic dissociation products.

Product Insight:

The cell dissociation market is categorized into enzymatic dissociation products, instruments & accessories, and non-enzymatic dissociation products. A range of enzymes is utilized in research for various purposes. Enzymatic dissociation products hold the lion's market share.

Trypsin, collagenase, elastase, and hyaluronidase are often used in enzymatic dissociation products. Enzymes are deployed in stem cell research and cell biology studies for cell and tissue dissociation, and single-cell harvesting. The use of enzymes for cell dissociation is fairly prevalent.

Ask our Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-16892

Regional Viewpoint:

In 2023, North America is going to have a high-income share. Rising cancer and chronic illness, strong trend of research and development investments, acquisitions, and collaboration by companies are the factors driving the market growth in North America.

The rising frequencies of chronic diseases in developing countries and increased government initiatives strengthen market growth in the Asia Pacific. The emerging use of cell-based assays and the availability of low-cost cell lysis and dissociation solutions may spur market expansion.

Throughout the forecast period, Europe's cell dissociation industry may account for the second leading revenue share. Europe's established biotech and pharmaceutical enterprises may contribute to cell dissociation market growth.

Key Takeaways:

  • The enzymatic dissociation category is likely to lead the market, accounting for almost 47.90% of sales in 2023.
  • From 2023 to 2033, the non-enzymatic segment in the cell dissociation industry is likely to expand at a significant CAGR.
  • In 2023, the tissue dissociation type segment is dominant, accounting for 56.55% of the cell dissociation industry.
  • Throughout the predicted period, the cell detachment type segment may blossom at a swift CAGR.
  • In 2023, the pharmaceutical and biotechnology firms’ end-user segment is likely to dominate, accounting for 71.60% of the cell dissociation industry.
  • North America is likely to lead the cell dissociation industry, accounting for 37.20% of the market in 2023.
  • During the predicted period, Asia Pacific to exhibit a significant CAGR.

Economic Environment:

Leading cell dissociation manufacturers are investing in toxicity and efficacy investigations involving cell dissociation enzymes. This aspect is predicted to power substantial growth in the cell dissociation market during the forecast years.

To increase the industry footprint, cell dissociation manufacturers implement a variety of initiatives such as partnerships, mergers, acquisitions, and expansions.

For More Report Customization, connect with us at https://www.futuremarketinsights.com/customization-available/rep-gb-16892

Strategic Progressions for Cell Dissociation:

Acquisitions:

  • December 8, 2021

PPD, Inc., a prominent provider of clinical research services, was acquired by Thermo Fisher Scientific Inc. The acquisition was valued at around US$ 17.4 billion and designed to boost Thermo Fisher Scientific's position in the life sciences sector.

  • April 9, 2020

Celsee, Inc., a leading manufacturer of single-cell analysis equipment, was acquired by Bio-Rad Laboratories, Inc. The acquisition sought to broaden Bio-Rad Laboratories' product offerings in the single-cell analysis industry.

  • June 1, 2020

Becton, Dickinson, and Company purchased Straub Medical AG, a leading provider of medical equipment for the diagnosis and treatment of venous disorders. The acquisition sought to broaden Becton, Dickinson and Company's product portfolio in the vascular access market.

Key Players:

  • HiMedia Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Thermo Fisher Scientific
  • Sartorius AG
  • S2 Genomics, Inc.
  • Danaher Corp.
  • STEMCELL Technologies
  • BD
  • Miltenyi Biotec
  • PAN-Biotech

Interested in buying this report – now get it at a discounted price now.

Key Segments:

Cell Dissociation Industry by Product:

  • Enzymatic dissociation
  • Non-enzymatic dissociation
  • Instruments & Accessories

Cell Dissociation Industry by Type:

  • Cell dissociation for Tissue Dissociation
  • Cell dissociation for Cell Detachment

Cell Dissociation Industry by End User:

  • Cell dissociation for Pharmaceutical and Biotechnology Companies
  • Cell dissociation for Research and Academic Institutes

Cell Dissociation Industry by Region:

  • Cell dissociation in North America Market
  • Cell dissociation in Latin America Market
  • Cell dissociation in Europe Market
  • Cell dissociation in East Asia Market
  • Cell dissociation in South Asia and Pacific Market
  • Cell dissociation in The Middle East and Africa (MEA) Market

Table of Content (ToC):
1. Executive Summary | Cell Dissociation Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

Request a Complete TOC of this Report with figures https://www.futuremarketinsights.com/toc/rep-gb-16892

Explore FMI’s related ongoing Coverage on Healthcare Market Domain:

Stem Cell Therapies Market Size: The stem cell therapy market is expected to grow at a CAGR of 16.7% from 2022 to 2032. Factors such as expanding stem cell research activities and increasing approvals of GMP-certified facilities to generate stem cells are driving stem cell therapy market expansion.

Small Cell Lung Cancer (SCLC) Treatment Market Share: The small cell lung cancer (SCLC) Treatment market is anticipated to grow further, at a CAGR of 13.1%, from US$ 1009.82 Million in 2022 to US$ 3.47 Million in 2032.

Automated Cell Biology Systems Market Demand: By the end of 2022, the global automated cell biology systems market is anticipated to be worth US$ 14.1 Billion, and it will grow at a CAGR of 9.0% to reach an expected valuation of around US$ 33.5 Billion by the year 2032. 

Anaplastic Large Cell Lymphoma (ALCL) Therapeutics Market Growth: Valued at US$ 10.5 Billion in 2022, the global anaplastic large cell lymphoma (ALCL) therapeutics market is expected to develop at a CAGR of 5% over the next ten years. By the end of this forecast year in 2032, analysts anticipate the anaplastic large cell lymphoma (ALCL) therapeutics market share would be worth US$ 17.1 Billion.

High Density Cell Banking Market Overview: The high density (HD) cell banking market is estimated to secure an aggressive CAGR of 8.4% during the forecast period. The market projected the valuation at US$ 13.12 Billion in 2022 and is likely to be valued at US$ 29.39 Billion by 2032.

Advance Renal Cell Carcinoma Therapeutics Market Sales: The global advance renal cell carcinoma therapeutics market is projected to have a rapid-paced CAGR of 5.4% during the forecast period. The current valuation of the market is US$ 6.3 Billion in 2022. The market value of the advanced renal cell carcinoma therapeutics market is anticipated to reach a high of US$ 10.66 Billion by 2032. 

PD1 Non-Small Cell Lung Cancer Treatment Market Outlook: The global PD1 non-small cell lung cancer treatment market size is expected to surpass an impressive valuation of US$ 26.96 Billion in 2023 and is projected to reach US$ 61 Billion by 2033, growing at a CAGR of 8.51%

3D Cell Culture Market Analysis: The global 3D cell culture market stands at a net worth of US$ 1.15 Billion in 2022, and is predicted to surge ahead at a CAGR of 9.8% over the forecast period to attain a valuation of US$ 2.67 Billion by 2031.

Sickle Cell Anemia Market Trends: Sickle cell anemia is an inherited red blood cells disorder. In case of sickle cell anemia the cells die early, leaving a shortage of healthy red blood cells to transport oxygen in adequate amount to the organs.

Live Cell RNA Detection Market Forecast: Global Live Cell RNA Detection’ demand is anticipated to be valued at US$ 2,631.8 Million in 2022, forecast to grow at a CAGR of 8.4% to be valued at US$ 6,404.2 Million from 2022 to 2032.

About Future Market Insights (FMI):

Future Market Insights, Inc. (ESOMAR certified, Stevie Award - recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10 years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedInTwitterBlogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com